SUPERNUS PHARMACEUTICALS, INC. (SUPN) research

SUPERNUS PHARMACEUTICALS, INC.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$43.29
As of

SUPERNUS PHARMACEUTICALS, INC. (SUPN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-03.

As of . Source: SEC EDGAR filings for SUPN. Method and limitations.

SHARE THIS CARD

Share the SUPN intelligence card

A branded snapshot of SUPN: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion SUPN intelligence card preview
Post to X
LIVE TERMINAL

See SUPN live in the terminal

Track SUPN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live SUPN terminal, free

Active signals for SUPN

FREE, NO ACCOUNT

Every signal on SUPN, as it fires

You are seeing 5 of 17 signals recorded on SUPN since 2026-05-17.

The five above all landed on 2026-09-06. The other 12 were recorded on 4 other days. 12 of the 17 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in SUPN (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 868459108 · 2026Q2$179.2M0.06%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 868459108 · 2026Q2$68.8M0.09%,
CITADEL ADVISORS LLCCUSIP 868459108 · 2026Q2$63.9M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 868459108 · 2026Q2$55.1M0.04%,
D. E. Shaw & Co., Inc.CUSIP 868459108 · 2026Q2$35.7M0.02%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, SUPN

SUPN against its peers

SUPN's operating margin of -8.7% ranks in the 42nd percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricSUPNPeer medianPercentilen
Revenue FY719M USD451M USD5721
Gross marginn/a53.3%n/a7
Operating margin-8.7%8.5%4319
Net margin-5.4%0.6%4520
Return on equity-3.6%-19.3%5721
P / En/a14.6xn/a10

Peers (25): HRMY, GPCR, NKTR, OCUL, BHC, TRVI, NUVB, ANIP, OGN, AMLX, XERS, TARS, OMER, INVA, PAHC, ANRO, ALMS, AMPH, PCRX, LQDA, AMRX, ESPR, ACRS, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SUPN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more SUPN signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SUPNand get the insider, 13F, options, and confluence read in one view.

Open the live SUPN terminal, free